iCents eyes growth on rising cleanroom demand
The cleanroom and facility services provider is confident that the proceeds from its IPO will enable it to carry out its business strategies and plans as outlined in its prospectus.
In the third quarter ended March 31, iCents posted a net profit of RM1.8mil, or earnings per share of 0.37 sen, bringing its nine-month net profit to RM6.9mil, or 1.38 sen.
Quarterly revenue came in at RM18.8mil, bringing nine-month revenue to RM62.8mil.
On prospects, iCents said growth in Malaysia's electrical and electronics and pharmaceutical industries is expected to drive demand for cleanroom facilities, creating opportunities for industry players.
iCents is slated for listing on the ACE Market of Bursa Malaysia on July 17.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
6 days ago
- The Star
Master Tec posts record RM104.8mil quarterly revenue in 2Q
KUALA LUMPUR: Master TEC Group Bhd is actively enhancing its production capacity and energy efficiency through new machinery acquisitions and the installation of rooftop solar photovoltaic systems, supporting its commitment to sustainability and green energy transition The cable manufacturer said it recently entered into two strategic memoranda of understanding to drive future growth. 'These developments, coupled with ongoing efforts in export market growth, product innovation, and sustainability initiatives, position the group well to capture future opportunities and deliver long-term shareholder value,' Master Tec said. In the second quarter ended June 30 (2Q25), Master Tec posted a net profit of RM6.9mil, down 20.5%, or earnings per share of 0.68 sen, bringing its first-half net profit to RM11.4mil, or 1.12 sen. It recorded a record quarterly revenue of RM104.82mil in 2Q25, a 43.9% increase from RM72.85mil in the same quarter last year, lifting its first-half revenue to RM175.06mil. The group declared a first interim single-tier dividend of 0.69 sen per share for FY25, amounting to approximately RM7.04mil, rewarding shareholders for their continued support. 'We are pleased to report our highest-ever quarterly revenue in 2Q25, which reflects the growing strength of our manufacturing and trading operations, as well as the positive contributions from our infrastructure services business via Sediacom. 'This solid performance affirms the success of our strategic focus on diversified revenue streams and capacity expansion. As we continue to scale, our focus remains on operational efficiency, product quality, and strengthening our market reach,' chief executive officer Tee Kok Hwa said in a statement. Looking ahead, Master Tec remains optimistic about its prospects, supported by growing infrastructure investments under the 13th Malaysia Plan and the National Energy Transition Roadmap.
Malay Mail
07-08-2025
- Malay Mail
Pharmaniaga completes regularisation plan, set to exit PN17 by Q1 2026
KUALA LUMPUR, Aug 7 — Pharmaniaga Bhd has completed its Practice Note 17 (PN17) regularisation plan following the completion of its capital reduction exercise through the cancellation of RM520 million in issued share capital. In a statement yesterday, the pharmaceutical company said the step firmly sets the group on course to exit the PN17 status latest by the first quarter (1Q) of 2026. 'The capital reduction exercise, which involved the cancellation of RM520 million in issued share capital, was completed after confirmation was received today from the Registrar of Companies that all statutory requirements have been fulfilled. 'Following the completion of this exercise, the issued share capital of the group is RM249.62 million, comprising 6.55 billion shares,' it said. Pharmaniaga fell into PN17 status in February 2023, dragged by its RM552.3 million provision for 'slow-moving inventories' of Covid-19 vaccines. At the close of trading yesterday, the counter finished unchanged at 18.5 sen, with 28.69 million shares changing hands. — Bernama
Free Malaysia Today
06-08-2025
- Free Malaysia Today
Pharmaniaga completes regularisation plan, to exit PN17 early 2026
Pharmaniaga Bhd fell into PN17 status in February 2023, dragged by its RM552.3 million provision for 'slow-moving inventories' of Covid-19 vaccines. KUALA LUMPUR : Pharmaniaga Bhd has completed its Practice Note 17 (PN17) regularisation plan following the completion of its capital reduction exercise through the cancellation of RM520 million in issued share capital. The pharmaceutical company said this step firmly sets the group on course to exit the PN17 status latest by the first quarter of 2026. 'The capital reduction exercise, which involved the cancellation of RM520 million in issued share capital, was completed after confirmation was received today from the registrar of companies that all statutory requirements have been fulfilled. 'Following the completion of this exercise, the issued share capital of the group is RM249.62 million, comprising 6.55 billion shares,' it said in a statement. Pharmaniaga fell into PN17 status in February 2023, dragged by its RM552.3 million provision for 'slow-moving inventories' of Covid-19 vaccines. At the close of trading today, the counter finished unchanged at 18.5 sen, with 28.69 million shares changing hands.
